Low‐Dose Nivolumab in Various Cancers: A Real‐World Exploratory Analysis in Resource‐Constrained Settings
Subhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr Jha · 2026
Read Low‐Dose Nivolumab in Various Cancers: A Real‐World Exploratory Analysis in Resource‐Constrained Settings by Subhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr Jha (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13680289.txt.
Description
Subhas Pandit and colleagues reviewed low-dose nivolumab use in two thousand twenty-six. Nivolumab is an immune therapy that helps fight cancer. Standard doses cost far too much for many patients. Clinics in resource-limited settings use much smaller fixed doses. The team gathered records from patients with varied cancers. Doses were given every three weeks.
Disease control held in about two-thirds of patients. Roughly half showed clear tumor shrinkage. Survival and side effects were tracked over months of follow-up. Results support wider testing of the cheap approach. Lower cost could open treatment to many more people. Careful trials must confirm these early signals.
Catalog record
| CREATOR | Subhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr Jha |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |